

# Chicago Politician Contacts U.S Attorneys General to Investigate the Approval of \$2.8 million Bluebird Bio Drug Zynteglo

LOS ANGELES, CA, UNITED STATES,  
September 30, 2022 /

EINPresswire.com/ -- Carl Segvich, Chicago Committeeman, has written to all Attorneys General in the United States, demanding an investigation surrounding the price of the Bluebird Bio product Zynteglo.


Committeeman Segvich, who has fought corruption on both sides of the political aisle since being elected in 2008, references the New York Supreme Court case 150856/2017 involving Bluebird Bio. At issue are the immense problems surrounding their price demands, ethics, and efficacy with the gene therapy purported to

cure Sickle Cell Disease and Thalassemia. "The proof," Mr. Segvich says, "is appalling. Big pharma gangsters literally get away with murdering patients. They do this by illegal activity, which in the case of Bluebird Bio, suppresses safer and more affordable competition.

The price of \$2.8 million means that Bluebird Bio will make an estimated \$2.5 million dollars per patient treated. This is absurd and an insult to every single US citizen." Just last year, Bluebird was rejected out of Europe for demanding \$1.8 million for the same therapy now priced and partially approved at \$2.8 million in the United States.

Segvich, who has represented an ethnically and racially-mixed area of Chicago for fourteen years, says that he fights for all of his constituents. This situation, he explains, particularly targets his African American voters, many of whom have Sickle Cell Disease themselves or within their families. It is estimated that 100,000 African Americans are afflicted with Sickle Cell Disease.

Zynteglo, or Betibeglogene Autotemcel/beti-cel has only been approved for Thalassemia



**NICK LESCHLY**  
Former CEO of Bluebird Bio (2018, \$11B median market cap)

**Pocketed \$24 Million in 2018\***, while **raising the gene therapy price for Sickle Cell Disease and Thalassemia \$2 million dollars per patient.**

Excerpted Graphic "Nick Leschly" from Megan Euker's exhibition "THE CURE" at the International Museum of Surgical Science Chicago, February - June 2020  
<https://imss.org/megan-euker-the-cure/>

patients. Historically, in the United States, most Thalassemia patients have origins from Northern Africa, Italy, and Greece.

Bluebird is applying to use the exact same product for Sickle Cell Disease patients, but using the name LentiGlobin. LentiGlobin has additionally been put on clinical hold due to safety concerns arising in clinical trials.

Segvich says that it is time for the US Attorneys General to stop politicizing their offices for personal gain and begin exercising their oath of office – protecting citizens.

“We have watched Merck, GSK, Purdue, and recently, the Sackler family, murder millions of Americans through their atrocious greed. When I say that these criminals are passing their racket from generation to generation, I’m talking about the Leschly family,” says Segvich.

The Chicago committeeman continues to elaborate that Jan Leschly was the head of Beecham Smith Kline (today GSK) when they lied about the drug Paxil, concealing evidence that it creates suicidal tendencies in children and adolescents. The tears of mothers and fathers flowed like the great Niagara.

Jan Leschly’s son, Nick Leschly, was the CEO of Bluebird Bio when Dr. Michel Sadelain’s gene therapy product for Sickle Cell Disease and Thalassemia was sabotaged. The New York Supreme Court’s documents have exposed that Mr. Leschly himself admitted to the superiority of the


competing product, also demonstrated in PowerPoints shared with his board. These powerpoints declare that the safer product must be destroyed in order to add \$200,000,000 to Bluebird’s bottom line.

The dead children must not be forgotten. Big pharma’s generational deadly fraud must end. This is the moral mandate of our times. The families deserve closure.

“

Big pharma gangsters literally get away with murdering patients. They do this by illegal activity, which in the case of Bluebird Bio, suppresses safer and more affordable competition.”

*Carl Segvich, Chicago Committeeman*



**JAN LESCHLY**  
CEO OF SmithKline Beecham (maker of Paxil), 1994 - May 2000, father of Nick Leschly

Paxil began being sold in 1994 and risks of the drug were **COVERED UP TO THE PUBLIC UNTIL 2001.**

In 2006 alone, **19.6 MILLION** prescriptions were written for Paxil.

Paxil is also known as Paroxetine and Seroxat.  
\*Paroxetine: Wikipedia.

**Estimated that OVER 300 MILLION prescriptions were written in 26 years.**

**Patients taking Paxil were nearly seven times more likely to attempt suicide than those on placebo.**  
\*Generic Paxil Suicide Lawsuit: Baum Hedlund Law Firm, Baum Hedlund, 5 Dec. 2018.

Glaxo hired a company to prepare a medical journal article that downplayed Paxil's safety risks, including increased risk of suicide, and misrepresented data to trump up the positive results of the study.  
Alexandra Sifferlin, "Breaking Down GlaxoSmithKline's Billion-Dollar Wrecking," Time, 5 July 2012.

**GlaxoSmithKline to Plead Guilty and Pay \$3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data.**  
Press Release from United States Department of Justice, Monday, July 2, 2012.


**The number of suicides caused by this drug are in the hundreds of thousands in the years of its existence.**

Graphic "Jan Leschly" from Megan Euker's exhibition "THE CURE" at the International Museum of Surgical Science Chicago, February - June 2020  
<https://imss.org/megan-euker-the-cure/>

Aurora DeRose  
Boundless Media Inc.  
+19518700099 ext.  
[email us here](#)



Still from video Patrick Girondi: RICO and Big Pharma/Flight of the Rondone: High School Dropout VS Big Pharma (GSK)



Still from video Patrick Girondi: RICO and Big Pharma/Flight of the Rondone: High School Dropout VS Big Pharma (Sackler/Purdue)

This press release can be viewed online at: <https://www.einpresswire.com/article/593576675>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.